<DOC>
	<DOCNO>NCT01796522</DOCNO>
	<brief_summary>Hypothesis : Both nifedipine progesterone widely use clinical practice maintenance tocolytic therapy episode threaten preterm delivery . Nevertheless , insufficient evidence justify routine use . The present study aim evaluate efficacy safety tocolytic drug maintenance tocolysis management threaten preterm delivery . Materials method : Phase III clinical trial , evaluate efficacy safety nifedipine progesterone maintenance tocolytic therapy 34th week pregnancy randomize woman episode threaten preterm delivery . Pregnant woman singleton pregnancy go evaluate , intact membrane cervical length less equal 25 mm , receive acute tocolysis atosiban . They randomize receive maintenance tocolysis nifedipine ( 60 mg / day orally ) progesterone ( 200 mg / day vaginally ) week 34 gestation . Therefore include patient receive treatment proven agree efficacy , decrease recurrence threaten preterm delivery , prolongation gestation subsequent good perinatal outcome . During course pregnancy , patient monitor outpatient obstetrics , thus check adequate compliance . Monitoring continue end delivery collection newborn data . The study single-blind , since blind evaluator . The drug treatment allow / clinical trial indicate data sheet drug . If patient take antihypertensive treatment continue pregnancy , dose adjustment do need . Data collect case report data ( CRD ) . The end test consider last recruited patient complete gestation ( deliver vaginally cesarean ) , data newborn collect . If serious adverse event occur patient , woman immediately finish clinical trial follow complete resolution episode . Treatment go consider effective birth occur 37 week pregnancy satisfactory perinatal outcome . The drug go consider safe cause adverse event pregnant woman , serious . Number Subjects : 50 pregnant woman Diagnosis main criterion inclusion exclusion : Inclusion Criteria - Pregnant woman singleton pregnancy intact membrane pass episode threaten preterm delivery ( uterine contraction cervical change ) successfully treat atosiban acute tocolytic therapy . - Cervical length ≤ 25 mm . Exclusion Criteria - ≥ 3 cm cervical dilation , multiple pregnancy , maternal medical contraindication tocolysis nifedipine , atosiban progesterone , obstetric contraindication tocolytic treatment ( severe preeclampsia , intrauterine infection , placental abruption , fetal abnormality incompatible life , fetal death ) . Investigational product , dose mode administration : After successful treatment acute preterm labor atosiban , compare safety efficacy maintenance tocolytic therapy nifedipine 60 mg / day orally progesterone 200 mg / day vaginally . Therapeutic group : C08CA05 Nifedipine . G03DA04 micronized progesterone . Route administration : nifedipine orally . Progesterone vaginally . Dose : Nifedipine 60 mg / day . Progesterone 200 mg / day . Duration treatment : From resolution acute episode threaten preterm labor 34 week gestation . Reference treatment , dose mode administration : Current evidence question utility maintenance tocolytic therapy . No reference treatment currently define .</brief_summary>
	<brief_title>Utility Tocolytic Therapy Maintenance Tocolysis Management Threatened Preterm Delivery</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Tocolytic Agents</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Pregnant woman singleton pregnancy intact membrane pass episode threaten preterm delivery ( uterine contraction cervical change ) successfully treat atosiban acute tocolytic therapy . Cervical length ≤ 25 mm . ≥ 3 cm cervical dilation , multiple pregnancy , maternal medical contraindication tocolysis nifedipine , atosiban progesterone , obstetric contraindication tocolytic treatment ( severe preeclampsia , intrauterine infection , placental abruption , fetal abnormality incompatible life , fetal death )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>